Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI

D. M. Riviere¹ · E. J. M. van Geenen² · B. M. van der Kolk³ · I. D. Nagtegaal⁴ · S. A. Radema⁵ · C. J. H. M. van Laarhoven³ · J. J. Hermans¹

Published online: 18 January 2019 © The Author(s) 2019

Abstract

Purpose To explore the value of gadolinium-enhanced MRI combined with diffusion-weighted MRI (Gd-enhanced MRI with DWI) in addition to contrast-enhanced CT (CECT) for detection of synchronous liver metastases for potentially resectable pancreatic cancer.

Methods By means of a retrospective cohort study we included patients with potentially resectable pancreatic cancer on CECT, who underwent Gd-enhanced MRI with DWI between January 2012 and December 2016. A single observer evaluated MRI and CT and was blinded to imaging, pathology, and surgery reports. Liver lesions were scored in both modalities, using a 3-point scale: 1-benign, 2-indeterminate, 3- malignant (i.e., metastasis). The primary outcome parameters were the presence of liver metastases on Gd-enhanced MRI with DWI and the sensitivity of Gd-enhanced MRI with DWI for synchronous liver metastases.

Results We included 66 patients (42 men, 24 women; median age 65 years, range 36–82 years). In 19 patients, liver metastases were present, which were confirmed by histopathology (n = 12), ¹⁸FDG-PET (n = 6), or surgical inspection (n = 1). Gd-enhanced MRI with DWI showed metastases in 16/19 patients (24%), which resulted in a sensitivity of 84% (95% CI 60–97%). Contrast-enhanced MRI showed 156 and DWI 397 metastases (p = 0.051), and 339 were particularly small (<5 mm).

Conclusions In this study, Gd-enhanced MRI with DWI detected synchronous liver metastases in 24% of patients with potentially resectable pancreatic cancer on CECT with a sensitivity of 84%. Diffusion-weighted MRI showed a greater number of metastases than any other sequence, particularly small metastases (<5 mm).

Keywords Pancreatic cancer · Pancreatic ductal carcinoma · Diffusion-weighted MRI · Metastases · Liver

Introduction

Pancreatic cancer is one of the most lethal forms of cancer with a 5-year relative survival rate of 6% reported by the American Cancer Society [1]. Total deaths due to pancreatic cancer are increasing dramatically and expected to become the second leading cause of cancer-related deaths before 2030 [2, 3]. Surgery of localized pancreatic cancer offers the only realistic chance to cure. Approximately 10–20% of patients do have unexpected liver metastases, peritoneal carcinomatosis, or locally advanced disease at the time of surgery [4–6]. More than 50% of all liver metastases develop in the first six months postoperatively, even in patients with early tumor stage [7]. These findings
suggest that liver metastases are already present at the time of surgery, which is supported by the mathematical model by Haeno et al., predicting that patients likely harbor metastases at diagnosis [8]. These synchronous liver metastases are not identified pre-operatively, as they are too small to be detected by routine preoperative ultrasound and contrast-enhanced CT (CECT) [9].

International guidelines advise CECT for routine diagnosing and staging of pancreatic cancer, whereas MRI is mostly used for characterization of indeterminate liver lesions [10]. CECT allows accurate assessment of the relationship between the tumor and critical arterial and venous structures [11]. However, the detection of subcentimeter metastases by CECT poses a greater challenge. Even if subcentimeter liver lesions are identified on a preoperative CT scan, the ability to precisely characterize those lesions as malignant is limited [12].

Nowadays, diffusion-weighted MR imaging (DWI) is increasingly used for hepatic imaging and has been shown to be a valuable tool in both detection and characterization of focal liver lesions with a sensitivity ranging from 86 to 97% and 60 to 91% for subcentimeter lesions [13–16]. Most studies have been performed for liver metastases of colorectal cancer. There are limited studies performed in pancreatic cancer, all concluding that additional MRI is useful in detecting liver metastases. Most studies used 1.5T scanners [9, 17–20]. In the 3.0T scanners, the increased signal-to-noise ratio can be translated into a higher resolution, and the improved contrast-to-noise ratio of gadolinium-based contrast agent can both contribute to improved lesion detection and characterization [21]. Liver-specific contrast agent was used in the studies by Ito et al., Motosugi et al. and Chew et al. for the detection of liver metastases [17, 19, 22]. In the ESGAR consensus statement, gadoxetate disodium is recommended for the diagnosis and characterization of malignant liver lesions in non-cirrhotic livers [23]. Aside from the associated higher costs, the relative hepatic enhancement could be negatively influenced by high serum bilirubin levels, which is common in patients with obstructive jaundice in pancreatic cancer of the head [24]. In this retrospective study, we evaluated the sensitivity of nonspecific extracellular gadolinium contrast-enhanced MRI (Gd-enhanced MRI) combined with DWI for synchronous liver metastases in potentially resectable pancreatic cancer on a 3T MR scanner.

Materials and methods

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Setting and participants

All patients older than 18 years with potentially resectable pancreatic cancer without liver metastases on CECT and additional Gd-enhanced MRI with DWI performed in our hospital from January 2012 to December 2016 were eligible for inclusion. Patients were recruited from the Radiology Information System. MRI was routinely performed in our center in all patients with potentially resectable disease or indeterminate liver lesions on CECT. Patients with locally resectable or borderline resectable pancreatic cancer were included. Resectability was established using criteria of the Dutch Pancreatic Cancer Group (PREOPANC trial, DPCG 2012). Exclusion criteria were local or systemic treatment for pancreatic cancer prior to imaging, locally advanced pancreatic cancer on CECT, incomplete liver imaging, and a time interval between CT and MRI or imaging and surgery of more than 2 months. The primary outcome parameters were the presence of liver metastases on Gd-enhanced MRI with DWI and the sensitivity of Gd-enhanced MRI with DWI for synchronous liver metastases. The secondary endpoint was the number of lesions suspicious for metastases detected by the different MRI sequences. Confirmation of liver metastases was obtained by histopathology, 18FDG-PET, and surgical findings. Explorative surgery was performed in all patients with (borderline) resectable tumors without histopathological proof or 18FDG-PET confirmation of metastases. Demographic characteristics were collected from the electronic medical records. Survival rates were obtained from the general practitioners in October 2015 and were updated in January 2018 from data in the electronic medical records.

CT technique

CECT was performed in different hospitals and produced at different models of 16- and 64-row multidetector CT scanners. Only high-quality datasets with image acquisition in the portal-venous phase and slice thickness of 3–5 mm were included for analysis.

MRI technique

All MR imaging of the abdomen was performed in our academic tertiary referral center on a 3.0 Tesla system (Magnetom Skyra, Siemens Healthcare, Erlangen, Germany). The imaging protocol is displayed in Table 1. The protocol consisted of a T1-weighted axial in- and opposed
phase gradient-echo VIBE, a half Fourier acquisition single-shot turbo spin-echo (HASTE), pre- and post-contrast T1-weighted 3D gradient-echo VIBE, and a respiratory triggered single-shot spin-echo echoplanar DWI in the transverse plane with monopolar diffusion gradients along three orthogonal directions with b-values of 0/50, 500, and 800 s/mm², using \( d = 10.1 \) ms and \( D = 33.5 \) ms. Fifteen ml of gadoterate meglumine 0.5 mmol/mL (Dotarem, Guerbet, Villepinte, France) was injected in an antecubital vein at 2.5 ml/s with a saline flush (NaCl 0.9%) of 20 ml at 2.5 ml/s using a pump injector (Optistar Elite, Mallinckrodt, Dublin, Ireland). MR cholangiopancreatographic images were also obtained; these images were not used in this study.

**Image interpretation**

MR images were consecutively reviewed by a radiologist (JH) with 14 years of experience in abdominal and pancreas imaging, on a commercial PACS workstation (Impax, Agfa Healthcare, Belgium). The observer was blinded to all clinical information, pathology reports, and the original radiology report, aside from the diagnosis of pancreatic cancer. In both modalities, liver lesions were scored using a 3-point scale: 1-benign, 2-indeterminate, 3-malignant (i.e., metastasis). Number, size, location, and imaging characteristics and the presumed diagnosis of the lesion were noted. Benign lesions were diagnosed using established imaging criteria [25–27]. On CECT, hypodense lesions that show typical features of a simple cyst (fluid attenuation measurements, round-oval, well-defined borders, no contrast enhancement), a hemangioma (localization next to vessels, peripheral nodular enhancement, centripetal fill-in), or focal fatty infiltration (geographic hypodense area, angular margins, typical location) are classified as benign lesions. Indeterminate liver lesions on CECT included hypodense liver lesions that were too small to be characterized. Metastases are hypodense lesions with rim enhancement. On MRI, metastases of pancreatic cancer are typically of moderately high to isointense signal intensity on T2W-images and mildly hypointense to isointense on T1W-images. Metastases can either be hypo- or hyper-vascular, and show homogeneous or peripheral enhancement (ring or wedge-shaped) in the arterial phase, homogeneous enhancement or peripheral enhancement with complete or incomplete centripetal progression in the portal-venous and interstitial phase [28]. On DWI, a lesion was classified as malignant (i.e., metastasis) when it was (moderately) hyperintense at \( b = 0/50 \) s/mm² and remained hyperintense at the highest \( b = 800 \) s/mm² and a lesion was considered benign when it was hyperintense at \( b = 0/50 \) s/mm² and showed a substantial decrease in signal intensity at higher b-values (\( b = 500 \) and 800 s/mm²). If none of the criteria were met, a lesion was classified as indeterminate. For the analysis, indeterminate lesions were classified as benign, as in clinical practice indeterminate lesions that cannot be further classified will be regarded as benign unless proven otherwise by biopsy. Whenever more than ten malignant lesions (i.e., metastasis) per slice were present, the number of malignant lesions per slice was estimated in dozens.

**Statistical methods**

All data were processed using SPSS software (version 20, SPSS, Chicago, IL). The sensitivity of Gd-enhanced MRI with DWI was calculated with a 95% confidence interval (CI). ANOVA test was performed to determine the differences between the group with liver metastases and the group without liver metastases. Paired samples \( t \) test was used to determine the difference between contrast-enhanced MRI and DWI regarding detection of malignant

---

**Table 1** MR imaging parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>T1-weighted imaging in- and opposed phase (VIBE)</th>
<th>T2-weighted imaging (HASTE)</th>
<th>T1-weighted imaging (VIBE) pre- and post-contrast</th>
<th>Diffusion-weighted imaging (SPAIR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plane</td>
<td>Axial</td>
<td>Axial</td>
<td>Axial</td>
<td>Axial</td>
</tr>
<tr>
<td>Section thickness (mm)</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Intersection gap (mm)</td>
<td>0</td>
<td>0.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Repetition time (msec)</td>
<td>4.35</td>
<td>1600</td>
<td>1400</td>
<td>4.34</td>
</tr>
<tr>
<td>Echo time (msec)</td>
<td>2.45–1.33</td>
<td>95</td>
<td>87</td>
<td>1.89</td>
</tr>
<tr>
<td>Flip angle (degree)</td>
<td>9</td>
<td>90/160</td>
<td>90/180</td>
<td>9</td>
</tr>
<tr>
<td>Field of view (cm)</td>
<td>30</td>
<td>35</td>
<td>180</td>
<td>30</td>
</tr>
<tr>
<td>Matrix</td>
<td>320 × 195</td>
<td>320 × 256</td>
<td>320 × 195</td>
<td>320 × 195</td>
</tr>
<tr>
<td>Bandwidth (Hz/pix)</td>
<td>975</td>
<td>710/710</td>
<td>650</td>
<td>1736</td>
</tr>
</tbody>
</table>

---

Springer
lesions. The differences between various MRI sequences regarding lesion detection were compared using the Friedman test. Post hoc analysis with Wilcoxon signed-rank tests was conducted with a Bonferroni correction applied. Survival analysis was performed using Kaplan–Meier curves with the day of diagnosis on imaging as entry date and log-rank test to test for statistical significance. A p value of less than 0.05 was considered statistically significant.

Results

Patients

Sixty-six consecutive patients (median age 65 years, range 36–82 years) out of 93 patients with potentially resectable pancreatic cancer were eligible for inclusion. Twenty-seven patients were excluded for the following reasons: no confirmation of the presence or absence of malignant lesions (n = 4), local or systemic treatment prior to imaging (n = 3), artifacts or incomplete liver imaging (n = 8), and a time interval between imaging or imaging and surgery of more than two months (n = 12). Nineteen (29%) patients were diagnosed with liver metastases. Altogether 32 out of 47 patients without liver metastases underwent resection of the tumor. In the remaining 15 patients, the tumor was unexpectedly locally advanced (n = 12), metastasized intraperitoneally (n = 2), or the patient was too weak for surgery (n = 1). There was a significant difference in the survival between patients with liver metastases and without liver metastases (χ²(2) = 28.354, p = 0.000). Descriptives of included patients are described in Table 2.

Confirmation of findings

Confirmation of liver metastases was obtained by histopathology in twelve patients; only in two cases transabdominal ultrasound with biopsy was successful. In the remaining patients, histopathology was obtained intraoperatively (n = 9) or by autopsy (n = 1). In six patients without histological proof, preoperative ¹⁸FDG-PET showed avid lesions in the liver, suggestive of liver metastases.

Table 2 Descriptives

<table>
<thead>
<tr>
<th></th>
<th>Liver metastases 19 (29%)</th>
<th>No liver metastases 47 (71%)</th>
<th>Total population 66 (100%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>13 (68%)</td>
<td>29 (62%)</td>
<td>42 (64%)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>6 (32%)</td>
<td>18 (38%)</td>
<td>24 (36%)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>Median 64 (50–81)</td>
<td>Median 66 (36–82)</td>
<td>Median 65 (36–82)</td>
<td>0.828</td>
</tr>
<tr>
<td>Primary tumor location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head</td>
<td>15 (79%)</td>
<td>37 (79%)</td>
<td>52 (79%)</td>
<td></td>
</tr>
<tr>
<td>Body/tail</td>
<td>2 (11%)</td>
<td>7 (15%)</td>
<td>10 (15%)</td>
<td></td>
</tr>
<tr>
<td>Both</td>
<td>1 (5%)</td>
<td>3 (6%)</td>
<td>4 (6%)</td>
<td></td>
</tr>
<tr>
<td>Ca19.9</td>
<td>Median 430 (0–5297) (n = 16)</td>
<td>Median 155 (1–7400) (n = 42)</td>
<td>Median 191 (0–7400) (n = 58)</td>
<td>0.044</td>
</tr>
<tr>
<td>Tumor stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>–</td>
<td>27 (57%)</td>
<td>27 (41%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>–</td>
<td>17 (36%)</td>
<td>27 (26%)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>19 (100%)</td>
<td>3 (6%)</td>
<td>27 (33%)</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Curative resection</td>
<td>–</td>
<td>32 (68%)</td>
<td>32 (48%)</td>
<td></td>
</tr>
<tr>
<td>Palliative bypass</td>
<td>7 (37%)</td>
<td>6 (13%)</td>
<td>13 (20%)</td>
<td></td>
</tr>
<tr>
<td>Explorative laparotomy</td>
<td>3 (16%)</td>
<td>5 (11%)</td>
<td>8 (12%)</td>
<td></td>
</tr>
<tr>
<td>Supportive care or palliative chemotherapy</td>
<td>9 (47%)</td>
<td>4 (9%)</td>
<td>13 (20%)</td>
<td></td>
</tr>
<tr>
<td>Survival (weeks)</td>
<td>Median 18 ± 1.9</td>
<td>Median 60 ± 8.1</td>
<td>Median 47 ± 3.0</td>
<td>0.000</td>
</tr>
</tbody>
</table>

Out of the included 66 patients, 19 patients had confirmed synchronous liver metastases. In this table, the groups with and without liver metastases and the total study population are depicted. The number of patients and the corresponding percentages, the median and corresponding ranges are reported. The survival is displayed in weeks, with corresponding standard errors.
metastases. In one patient multiple liver metastases were confirmed by intraoperative inspection and palpation of the liver and peritoneal metastases were histologically proven. The absence of liver metastases in the remaining 46 patients was confirmed intraoperatively by inspection and palpation of the liver \((n = 43)\) and \(^{18}\)FDG-PET \((n = 4)\). The mean time interval between CECT and Gd-enhanced MRI with DWI was 15 days \((SD 12\) days) and 26 days \((SD 14\) days) between Gd-enhanced MRI with DWI and surgery.

**Lesion analysis**

Gd-enhanced MRI with DWI detected malignant lesions in 16 out of 19 patients with liver metastases. The sensitivity of Gd-enhanced MRI with DWI was 84\% \((95\% CI 60–97\%)\). The positive predictive value was 94\% \((95\% CI 69–99\%)\), and the negative predictive value was 94\% \((95\% CI 85–98\%)\). There was one false positive on a per-patient basis, in this patient one liver lesion with perilesional ring enhancement and persistent high signal intensity on DWI was characterized as malignant on Gd-enhanced MRI with DWI. There was no evidence of liver metastases during surgery and follow-up CECT after 1 year. There were three false negatives on a per-patient basis. In the first case, one indeterminate lesion in liver segment six on CECT was characterized as benign on Gd-enhanced MRI with DWI. However, intraoperative biopsy-proven metastasis in segment two was not detected on MRI. In the second case, there were neither liver lesions on CECT nor Gd-enhanced MRI with DWI. In the last case, one lesion was indeterminate on Gd-enhanced MRI with DWI, yet showed high uptake on preoperative \(^{18}\)FDG-PET and thus was classified as metastasis.

In the negative-on-CT group, the per-patient prevalence of liver metastases was 20\% \((9/44)\). MRI was of additional value in 16\% \((7/44)\). In the indeterminate-on-CT group, the per-patient prevalence of liver metastases was 45\% \((10/22)\). MRI was of additional value in 90\% of the patients \((20/22)\).

On a per lesion basis, Gd-enhanced MRI with DWI detected 397 malignant lesions in 16 out of 19 patients with liver metastases. Contrast-enhanced MRI detected 156 malignant lesions, whereas DWI detected 397 malignant lesions \((p = 0.051)\). In three patients, 20 to 50 malignant lesions were detected only by DWI. In one patient, even more than 100 malignant lesions were visible only on DWI \(\text{Fig. 1}\). Table 3 summarizes the detection rate of malignant lesions in the different sequences of Gd-enhanced MRI with DWI. There was a statistically significant difference in the number of malignant lesions detected by T2W-HASTE, T1W-VIBE precontrast, arterial phase, portal-venous phase, and DWI \((\chi^2(2) = 32.861, p = 0.000)\). Post hoc analysis with Wilcoxon signed-rank tests was conducted with a Bonferroni correction applied, resulting in a statistically significant difference with a \(p\) value of 0.005. DWI detected significantly more metastases compared to T2W-HASTE \((Z = – 3.181, p = 0.001)\), T1W-VIBE precontrast \((Z = – 3.183, p = 0.001)\), arterial phase \((Z = – 2.943, p = 0.003)\), and portal-venous phase \((Z = – 3.063, p = 0.002)\). Figures 2, 3, and 4 show examples of three different patterns of liver metastases of pancreatic cancer on Gd-enhanced MRI with DWI.

Ninety-five percent of all liver metastases detected on Gd-enhanced MRI with DWI were subcentimeter lesions: 85\% \(< 5\) mm, 10\% 6–10 mm, and 5\% \(> 10\) mm. Nine patients \((47\%)\) had oligometastatic liver disease \((i.e., \leq 5\) liver metastases \([29]\)) and eleven patients had polymetastatic liver disease.

**Discussion**

In this study, liver metastases were accurately diagnosed by Gd-enhanced MRI with DWI in 16 out of 66 \((24\%)\) patients initially diagnosed with potentially resectable pancreatic cancer on CECT. Adding a diffusion-weighted MRI to the contrast-enhanced MRI increased the number of detected metastases from 156 to 397. The combination of contrast-enhanced MRI and diffusion-weighted MRI yielded a high detection rate in previous studies, particularly in small metastases \([30]\). Metastases of pancreatic cancer are mostly small and multiple, which is consistent with the study by Danet et al. \([28]\), subcentimeter lesions comprising 95\% of all lesions. DWI seems particularly useful in the estimation of the metastatic load with the detection of metastases that are smaller than 5 mm.

The prevalence of liver metastases in this study was relatively high, 29\%. The reported prevalence of liver metastases in the previous studies varies from 4.9\% to 30\% \([9, 17–20, 22]\). Patients with borderline resectable tumors and patients with indeterminate liver lesions were included, with a higher probability of having liver metastases. Additionally, on Gd-enhanced MRI there were metastases with a hypervascular enhancement pattern. A CECT with only porto-venous phase might have decreased the detection of these hypervascular metastases and overall the ability to characterize focal liver lesions on CECT. These factors might attribute to the higher additional value of MRI in this study as compared to the previous studies. The sensitivity of combined contrast-enhanced and diffusion-weighted MRI was 84\%, which was comparable to other studies with sensitivities ranging from 73 to 100\% \([9, 17, 18, 22]\). Given the aggressiveness of pancreatic cancer and its tendency for rapid metastatic spread,
differences in sensitivity might be caused by differences in the time interval between Gd-enhanced MRI with DWI and the reference standard. The mean time interval in this study between CECT and Gd-enhanced MRI with DWI was 15 days and 26 days between Gd-enhanced MRI with DWI and surgery. A time interval of less than 20–25 days between imaging and any planned definitive therapy seems appropriate to grant accurate staging [4, 5, 31, 32]. Observer bias might have influenced the results of the study in favor of Gd-enhanced MRI with DWI, as only one observer re-evaluated the images, although in routine clinical practice images are also viewed by one observer, and the reported interobserver agreement for focal liver lesions in previous studies was good to excellent [15, 17, 18, 33–35].

A major problem was histopathological confirmation of the findings on Gd-enhanced MRI with DWI, as biopsy of all liver lesions is not possible and unethical in a living patient. Therefore, determining diagnostic accuracy on a per lesion basis is nearly impossible. Moreover, in our

| Table 3 Number of malignant lesions on different sequences of Gd-enhanced MRI with DWI |
|-----------------|----------------|----------------|----------------|----------------|----------------|
| Sequence        | T2W-MRI | T1W-MRI precontrast | T1W-MRI arterial | T1W-MRI portal-venous | DWI |
| ≤ 5 mm          | 13      | 9               | 100             | 90              | 339             |
| 6–10 mm         | 30      | 27              | 32              | 30              | 38              |
| > 10 mm         | 20      | 18              | 20              | 20              | 20              |
| Total           | 63      | 54              | 152             | 140             | 397             |

The number of suspected liver metastases on various sequences of Gd-enhanced MRI with DWI in patients with liver metastases
experience not all lesions on MRI are visible using either transabdominal or intraoperative ultrasound, therefore determining diagnostic accuracy on a per-patient basis remains challenging. In future clinical practice, MRI-guided biopsy with follow-up imaging could become an alternative strategy. In this study, there was one false positive on a per-patient basis; in previous studies false positives were also reported [17, 20, 22]. Therefore, at this moment we cannot deny patients surgery without histopathological proof of the radiological malignant liver lesions.

The increased safety of operations has led to more extensive local pancreas resections with venous and arterial reconstructions. Also, more effective chemotherapy protocols have been introduced, including combination therapies such as FOLFIRINOX. After neoadjuvant therapy in patients with borderline resectable pancreatic cancer or even locally advanced pancreatic cancer, secondary resection proved feasible with acceptable morbidity and survival rates [36]. Although still controversial, small studies and case reports have described select patients with oligometastatic hepatic metastases undergoing curative resection of the pancreas and the synchronous hepatic metastases [37, 38]. To benefit from these developments, adequate staging is a prerequisite and information on size, number, and distribution of liver metastases are of the utmost importance. Improved detection of liver metastases could reduce futile resection of the tumor with its associated morbidity and mortality in these patients with a markedly reduced life expectancy. Moreover, it offers the possibility to start palliative systemic chemotherapy earlier as there is no recovery period from the operation. Also, it can reduce palliative bypass surgery as the prognosis for metastatic disease is even worse than for locally advanced disease [39]. Patients with obstructive symptoms can successfully be treated with endoscopically placed biliary and enteric stents, which is a safe, efficacious, and cost-effective procedure with good clinical outcome [40]. Finally, improved detection of liver metastases during monitoring of (neo)adjuvant treatment could lead to a change in therapeutic strategy.

The retrospective nature of this study prevents a reliable calculation of the specificity, positive and negative predictive value of Gd-enhanced MRI with DWI versus CECT. Therefore, we started a large international multicenter prospective study to validate these results and to determine the diagnostic accuracy, implications for clinical decision making, and cost-effectiveness of Gd-enhanced MRI with DWI.

This study showed that Gd-enhanced MRI with DWI detected synchronous liver metastases in 24% of patients with potentially resectable pancreatic cancer on CECT with a sensitivity of 84%. Contrast-enhanced MRI showed 156 malignant lesions versus 397 malignant lesions with DWI, most of which were particularly small (< 5 mm).

**Funding** The authors state that this work has not received any funding.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**


